Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”
M. Untch, M. Rezai, S. Loibl, P.A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, K. Mehta, G. von MinckwitzVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70313-6
File:
PDF, 60 KB
english, 2008